These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 26261854)

  • 1. Anti-angiogenic nanotherapy via active targeting systems to tumors and adipose tissue vasculature.
    Sakurai Y; Kajimoto K; Harashima H
    Biomater Sci; 2015 Sep; 3(9):1253-65. PubMed ID: 26261854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in an active and passive targeting to tumor and adipose tissues.
    Sakurai Y; Kajimoto K; Hatakeyama H; Harashima H
    Expert Opin Drug Deliv; 2015 Jan; 12(1):41-52. PubMed ID: 25376864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular-targeted nanotherapy for obesity: unexpected passive targeting mechanism to obese fat for the enhancement of active drug delivery.
    Hossen MN; Kajimoto K; Akita H; Hyodo M; Harashima H
    J Control Release; 2012 Oct; 163(2):101-10. PubMed ID: 22982237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multifunctional Envelope-Type Nano Device: Evolution from Nonselective to Active Targeting System.
    Hayashi Y; Hatakeyama H; Kajimoto K; Hyodo M; Akita H; Harashima H
    Bioconjug Chem; 2015 Jul; 26(7):1266-76. PubMed ID: 25938819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ligand-based targeted delivery of a peptide modified nanocarrier to endothelial cells in adipose tissue.
    Hossen MN; Kajimoto K; Akita H; Hyodo M; Ishitsuka T; Harashima H
    J Control Release; 2010 Oct; 147(2):261-8. PubMed ID: 20647023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased tumor targeted delivery using a multistage liposome system functionalized with RGD, TAT and cleavable PEG.
    Mei L; Fu L; Shi K; Zhang Q; Liu Y; Tang J; Gao H; Zhang Z; He Q
    Int J Pharm; 2014 Jul; 468(1-2):26-38. PubMed ID: 24709209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Size-controlled, dual-ligand modified liposomes that target the tumor vasculature show promise for use in drug-resistant cancer therapy.
    Takara K; Hatakeyama H; Kibria G; Ohga N; Hida K; Harashima H
    J Control Release; 2012 Aug; 162(1):225-32. PubMed ID: 22728515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Failure of active targeting by a cholesterol-anchored ligand and improvement by altering the lipid composition to prevent ligand desorption.
    Yamamoto S; Sakurai Y; Harashima H
    Int J Pharm; 2018 Jan; 536(1):42-49. PubMed ID: 29126905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative assessments of crucial factors for a functional ligand-targeted nanocarrier.
    Hossen MN; Kajimoto K; Tatsumi R; Hyodo M; Harashima H
    J Drug Target; 2014 Aug; 22(7):600-9. PubMed ID: 24806515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic assessment of cytochrome C for the prevention of obesity through endothelial cell-targeted nanoparticulate system.
    Hossen MN; Kajimoto K; Akita H; Hyodo M; Ishitsuka T; Harashima H
    Mol Ther; 2013 Mar; 21(3):533-41. PubMed ID: 23295953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparative study between nanoparticle-targeted therapeutics and bioconjugates as obesity medication.
    Hossen N; Kajimoto K; Akita H; Hyodo M; Harashima H
    J Control Release; 2013 Oct; 171(2):104-12. PubMed ID: 23871959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced small interfering RNA delivery into cells by exploiting the additive effect between photo-sensitive peptides and targeting ligands.
    Lin W; Xie X; Yang Y; Liu H; Fu X; Chen Y; Liu H; Yang Y
    J Pharm Pharmacol; 2015 Sep; 67(9):1215-31. PubMed ID: 25880614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual-modified liposomes with a two-photon-sensitive cell penetrating peptide and NGR ligand for siRNA targeting delivery.
    Yang Y; Yang Y; Xie X; Wang Z; Gong W; Zhang H; Li Y; Yu F; Li Z; Mei X
    Biomaterials; 2015 Apr; 48():84-96. PubMed ID: 25701034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A non-covalent peptide-based strategy for ex vivo and in vivo oligonucleotide delivery.
    Crombez L; Morris MC; Heitz F; Divita G
    Methods Mol Biol; 2011; 764():59-73. PubMed ID: 21748633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. siRNA delivery: from lipids to cell-penetrating peptides and their mimics.
    Gooding M; Browne LP; Quinteiro FM; Selwood DL
    Chem Biol Drug Des; 2012 Dec; 80(6):787-809. PubMed ID: 22974319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Development of siRNA Delivery Targeting the Tumor Microenvironment with a New Functional Device].
    Sakurai Y
    Yakugaku Zasshi; 2019; 139(11):1357-1363. PubMed ID: 31685731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RNAi-mediated gene knockdown and anti-angiogenic therapy of RCCs using a cyclic RGD-modified liposomal-siRNA system.
    Sakurai Y; Hatakeyama H; Sato Y; Hyodo M; Akita H; Ohga N; Hida K; Harashima H
    J Control Release; 2014 Jan; 173():110-8. PubMed ID: 24120854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preparation of a Cyclic RGD: Modified Liposomal SiRNA Formulation for Use in Active Targeting to Tumor and Tumor Endothelial Cells.
    Sakurai Y; Hada T; Harashima H
    Methods Mol Biol; 2016; 1364():63-9. PubMed ID: 26472442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new peptide motif present in the protective antigen of anthrax toxin exerts its efficiency on the cellular uptake of liposomes and applications for a dual-ligand system.
    Kibria G; Hatakeyama H; Harashima H
    Int J Pharm; 2011 Jun; 412(1-2):106-14. PubMed ID: 21414394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polymer Nanoparticles Modified with Photo- and pH-Dual-Responsive Polypeptides for Enhanced and Targeted Cancer Therapy.
    Yang Y; Xie X; Yang Y; Li Z; Yu F; Gong W; Li Y; Zhang H; Wang Z; Mei X
    Mol Pharm; 2016 May; 13(5):1508-19. PubMed ID: 27043442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.